The stock of Zynex, Inc. (NASDAQ:ZYXI) is a huge mover today! The stock decreased 2.89% or $0.31 during the last trading session, reaching $10.4. About 200,846 shares traded. Zynex, Inc. (NASDAQ:ZYXI) has risen 181.11% since December 4, 2018 and is uptrending. It has outperformed by 181.11% the S&P500.
The move comes after 6 months negative chart setup for the $340.53M company. It was reported on Dec, 4 by Barchart.com. We have $9.67 PT which if reached, will make NASDAQ:ZYXI worth $23.84 million less.
Zynex, Inc. (NASDAQ:ZYXI) Ratings Coverage
Among 3 analysts covering Zynex (NASDAQ:ZYXI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zynex has $1200 highest and $10.7500 lowest target. $11.58’s average target is 11.35% above currents $10.4 stock price. Zynex had 4 analyst reports since August 2, 2019 according to SRatingsIntel. FBR Capital maintained Zynex, Inc. (NASDAQ:ZYXI) rating on Friday, August 2. FBR Capital has “Buy” rating and $10.7500 target. The firm has “Buy” rating by B. Riley & Co given on Tuesday, October 22.
More notable recent Zynex, Inc. (NASDAQ:ZYXI) news were published by: Prnewswire.com which released: “Zynex Announces 2019 Third Quarter Financial Results – PRNewswire” on October 29, 2019, also Investorplace.com with their article: “7 Stocks to Buy Down 10% in the Past Week – Investorplace.com” published on August 28, 2019, Finance.Yahoo.com published: “Is There An Opportunity With Zynex, Inc.’s (NASDAQ:ZYXI) 47% Undervaluation? – Yahoo Finance” on November 06, 2019. More interesting news about Zynex, Inc. (NASDAQ:ZYXI) were released by: Finance.Yahoo.com and their article: “Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)? – Yahoo Finance” published on September 06, 2019 as well as Finance.Yahoo.com‘s news article titled: “Here’s Why We Think Zynex (NASDAQ:ZYXI) Is Well Worth Watching – Yahoo Finance” with publication date: July 19, 2019.
Zynex, Inc., a medical technology company, designs, makes, and markets electrotherapy medical devices used for pain management and rehabilitation. The company has market cap of $340.53 million. The Company’s products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. It has a 38.52 P/E ratio. The firm also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.